Delivering breakthrough eye care solutions

MINIject® is seeking to transform the glaucoma treatment landscape with its distinctive, tissue-integrating STAR® material. MINIject® is currently the only commercially available minimally invasive glaucoma surgery (MIGS) implant that enhances natural flow in the supraciliary space, and has been shown to deliver safe, meaningful and sustained control of intraocular pressure (IOP).


MINIject® is a novel MIGS device for patients with open-angle glaucoma, made of an innovative medical-grade silicone material called STAR®. MINIject® has been shown to safely and meaningfully control eye pressure and glaucoma through:


STAR® material is composed of a multi-channel network of hollow spheres making it soft and flexible while encouraging bio-integration. iSTAR Medical believes this distinctive combination of material and outflow enables MINIject® to deliver sustained efficacy. 


MINIject® is only available for sale in the European Union, the UK and Switzerland.

Denis P, Hirneiß C, Durr GM, et al. Br J Ophthalmol 2020;0:1–6


Glaucoma worldwide

glaucoma is the 1 st leading cause of irreversible blindness in the world
age 60 + years of age is a major risk factor
affecting over 100 million people globally
every year, more than 2 million people globally are newly diagnosed with glaucoma
in western europe, around 14 % patients undiagnosed up to 74% in emerging markets such as India
With a wordwide average 24 % annual growth rate MIGS are the fastest growing glaucoma treatment

Source: Market Scope, “2021 Glaucoma Surgical Device Market Report”, July 2021; Jonas JB, Aung T, Bourne RR et al, “Glaucoma”, Lancet 2017; 390: 2083–93

iSTAR Medical

iSTAR Medical is a medtech company committed to delivering breakthrough eye care solutions through minimally-invasive implants designed for bio-integration. Our mission is to become the world leader in minimally invasive implants for glaucoma surgery.


iSTAR Medical received European approval for the MINIject MIGS device in late 2021 and began enrolment into an FDA-approved clinical trial (STAR-V) in the United States in 2021. Since 2023, it is also approved for implantation in Australia.



News items

scroll to up
Sign up to receive company news alerts